1. Клинические рекомендации МЗ РФ «Гастрит и дуоденит», 2024. Режим доступа: https://cr.minzdrav.gov.ru/preview-cr/708_2. Ссылка активна на 19.03.2025 [Klinicheskie rekomendatsii MZ RF «Gastrit i duodenit», 2024. Available at: https://cr.minzdrav.gov.ru/preview-cr/708_2. Accessed: 19.03.2025 (in Russian)]. 
2. Ивашкин В.Т., Маев И.В., Лапина Т.Л., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации «Эндоскопическое общество РЭНДО» по диагностике и лечению гастрита, дуоденита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(4):70-99 [Ivashkin VT, Maev IV, Lapina TL, et al. Clinical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70-99 (in Russian)]. DOI:10.22416/1382-4376-2021-31-4-70-99
3. Осипенко М.Ф., Бикбулатова Е.А., Шакалите Ю.Д., и др. Резистентность Helicobacter pylori к кларитромицину в Новосибирске. Экспериментальная и клиническая гастроэнтерология. 2012;8:15-7 [Osipenko MF, Bikbulatova EA, Shakalite YuD, et al. Resistance of Helicobacter pylori to  clarithromycin in Novosibirsk. Experimental and Clinical Gastroenterology. 2012;8:15-7 (in Russian)]. EDN: SEPVAB
4. Симаненков В.И., Захарова Н.В., Жебрун А.Б., и др. Резистентность Helicobacter pylori к антимикробным препаратам по результатам бактериологического тестирования. Лечащий врач. 2015;4:91-5 [Simanenkov VI, Zakharova NV, Zhebrun AB, et al. Resistance of Helicobacter pylori to antimicrobial drugs according to the results of bacteriological testing. Lechashchii vrach. 2015;4:91-5 (in Russian)]. EDN: TPLKMR
5. Барышникова Н.В., Денисова Е.В., Корниенко Е.А., и др. Эпидемиологическое исследование резистентности Helicobacter pylori к кларитромицину у жителей Санкт-Петербурга c язвенной болезнью. Экспериментальная и клиническая гастроэнтерология. 2009;5:73-6 [Baryshnikova NV, Denisova EV, Kornienko EA, et al. Epidemiological study of Helicobacter pylori resistance to clarithromycin in St. Petersburg residents with peptic ulcer disease. Experimental and Clinical Gastroenterology. 2009;5:73-6 (in Russian)]. EDN: MVAHWR
6. Sun Q, Liang X, Zheng Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010;15(3):233-8. DOI:10.1111/j.1523-5378.2010.00758.x
7. Malfertheiner P. Infection: Bismuth improves PPI-based triple therapy for H. pylori eradication. Nat Rev Gastroenterol Hepatol. 2010;7(10):538-9. DOI:10.1038/nrgastro.2010.131
8. McNicholl AG, Bordin DS, Lucendo A, et al. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clin Gastroenterol Hepatol. 2020;18(1):89-98. DOI:10.1016/j.cgh.2019.03.048
9. Ткаченко Е.И., Успенский Ю.П., Барышникова Н.В. Оптимизация лечения больных с заболеваниями, ассоциированными с инфекцией Helicobacter pylori: обоснование необходимости использования препаратов висмута. Экспериментальная и клиническая гастроэнтерология. 2009;6:116-21 [Tkachenko EI, Uspenskii YuP, Baryshnikova NV. Optimization of treatment of patients with diseases associated with Helicobacter pylori infection: justification of the need to use bismuth preparations. Experimental and Clinical Gastroenterology. 2009;6:116-21 (in Russian)]. EDN: YQIDJV
10. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 1988;2(8626-7):1437-42. DOI:10.1016/s0140-6736(88)90929-4
11. Лазебник Л.Б., Васильев Ю.В., Щербаков П.Л., и др. Helicobacter pylori: распространенность, диагностика, лечение. Экспериментальная и клиническая гастроэнтерология. 2010;(2):3-7 [Lazebnik LB, Vasilev YuV, Shcherbakov PL, et al. Helicobacter pylori: prevalence, diagnosis, treatment. Experimental and Clinical Gastroenterology. 2010;(2):3-7 (in Russian)]. EDN: MVAIIF
12. Хомерики Н.М., Морозов И.А. Особенности цитопротекции в желудке и некоторые аспекты фармакологического действия препаратов висмута. Медицинский совет. 2017;11:112-9 [Khomeriki NM, Morozov IA. Peculiarities of cytoprotection in the stomach and some aspects of pharmacological action of bismuth drugs. Medical Council. 2017;(11):112-9 (in Russian)]. DOI:10.21518/2079-701X-2017-112-119 
13. Bagchi D, McGinn TR, Ye X, et al. Mechanism of gastroprotection by bismuth subsalicylate against chemically induced oxidative stress in cultured human gastric mucosal cells. Dig Dis Sci. 1999;44(12):2419-28. DOI:10.1023/a:1026618501729
14. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261-70. DOI:10.1586/egh.10.25
15. Haruma K, Ito M. Review article: clinical significance of mucosal-protective agents: acid, inflammation, carcinogenesis and rebamipide. Aliment Pharmacol Ther. 2003;18(Suppl. 1):153-9. DOI:10.1046/j.1365-2036.18.s1.17.x
16. Hayashi S, Sugiyama T, Amano K, et al. Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother. 1998;42(8):1895-9. DOI:10.1128/AAC.42.8.1895
17. Andreev DN, Maev IV, Dicheva DT. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med. 2019;8(9):1498. DOI:10.3390/jcm8091498
18. Hayashi S, Sugiyama T, Yokota K, et al. Combined effect of rebamipide and ecabet sodium on Helicobacter pylori adhesion to gastric epithelial cells. Microbiol Immunol. 2000;44(7):557-62. DOI:10.1111/j.1348-0421.2000.tb02534.x
19. Arakawa T, Higuchi K, Fujiwara Y, et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50(Suppl. 1):S3-S11. DOI:10.1007/s10620-005-2800-9
20. Haruma K, Ito M, Kido S, et al. Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci. 2002;47(4):862-7. DOI:10.1023/a:1014716822702
21. Kamada T, Sato M, Tokutomi T, et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015;2015:865146. DOI:10.1155/2015/865146
22. Симаненков В.И., Маев И.В., Ткачева О.Н., и др. Эпителий-протективная терапия при коморбидных заболеваниях. Практические рекомендации для врачей. Терапевтический архив. 2022;94(8):940-56 [Simanenkov VI, Maev IV, Tkacheva ON, et al. Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(8):940-56 (in Russian)]. DOI:10.26442/00403660.2022.08.201523
23. Ohashi H, Maruyama T, Higashi-Matsumoto H, et al. A novel binding assay for metabotropic glutamate receptors using [3H] L-quisqualic acid and recombinant receptors. Z Naturforsch C J Biosci. 2002;57(3-4):348-55. DOI:10.1515/znc-2002-3-425
24. Shevtsov MA, Smagina LV, Kudriavtceva TA, et al. Glu-Trp-ONa or its acylated analogue (R-Glu-Trp-ONa) administration enhances the wound healing in the model of chronic skin wounds in rabbits. Drug Des Devel Ther. 2015;9:1717-27. DOI:10.2147/DDDT.S79665
25. Успенский Ю.П., Барышникова Н.В., Краснов А.А., и др. Актуальные вопросы профилактики рака желудка. Consilium Medicum. 2022;24(5):357-64 [Uspensky YP, Baryshnikova NV, Krasnov AA, et al. Topical issues of prevention of stomach cancer. Consilium medicum. 2022;24(5):357-64 (in Russian)]. DOI:10.26442/20751753.2022.5.201922
26. Успенский Ю.П., Барышникова Н.В., Краснов А.А., и др. Влияние Регастим Гастро на восстановление кислотопродукции в желудке по данным суточной рН-метрии у больных хроническим атрофическим гастритом. Экспериментальная и клиническая гастроэнтерология. 2022;198(2):40-7 [Uspensky Yu P, Baryshnikova NV, Krasnov AA, et al. The effect of Regasthym Gastro on the restoration of acid production in the stomach according to daily pH-metry in patients with chronic atrophic gastritis. Experimental and Clinical Gastroenterology. 2022;198(2):40-7 (in Russian)]. DOI:10.31146/1682-8658-ecg-198-2-40-47
27. Uspensky YP, Baryshnikova NV, Fominykh YA, et al. Alpha-Glutamyl-Tryptophan in the treatment of chronic atrophic gastritis, associated with Helicobacter pylori. From the edited volume «Helicobacter pylori Infection – An Up to Date on the Pathogenic Mechanisms, Diagnosis and Clinical Management». Available at: https://www.intechopen.com/online-first/84437. Accessed: 06.03.2024.
28. Барышникова Н.В., Успенский Ю.П., Калинина Е.Ю., и др. Эффективность альфа-глутамил-триптофана в купировании воспаления у больных хроническим атрофическим гастритом, ассоциированным с Helicobacter pylori. Доказательная гастроэнтерология. 2022;11(4):15-21 [Baryshnikova NV, Uspensky YuP, Kalinina EYu, et al. The effectiveness of alpha-glutamyl-tryptophan in relieving inflammation in patients with chronic atrophic gastritis associated with Helicobacter pylori. Dokasatelnaya Gastroenterologia. 2022;11(4):15-21 (in Russian)]. DOI:10.17116/dokgastro20221104115. 
29. Ткаченко Е.И., Успенский Ю.П., Барышникова Н.В. Оптимизация лечения заболеваний, ассоциированных с Helicobacter pylori. Врач. 2012;1:36-8 [Tkachenko EI, Uspenskiy YuP, Baryshnikova NV. Optimization of treatment for Helicobacter pylori-associated diseases. Vrach. 2012; 1:36-8 (in Russian)].
30. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut. 2012;61(5):646-64. DOI:10.1136/gutjnl-2012-302084
31. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. DOI:10.1136/gutjnl-2016-312288
32. Malfertheiner P, Megraud F, Rokkas T; European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;gutjnl-2022-327745. DOI:10.1136/gutjnl-2022-327745
33. Ивашкин В.Т., Лапина Т.Л., Маев И.В., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации, Научного сообщества по содействию клиническому изучению микробиома человека, Российского общества профилактики неинфекционных заболеваний, Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии по диагностике и лечению H. pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(6):72-93 [Ivashkin VT, Lapina TL, Maev IV, et al. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for Н. pylori Diagnostics and Treatment in Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):72-93 (in Russian)]. DOI:10.22416/1382-4376-2022-32-6-72-93
34. Лазебник Л.Б., Дехнич Н.Н., Ситкин С.И., и др. Helicobacter pylori, хеликобактериоз и ассоциированные заболевания (VIII Московские соглашения по диагностике и лечению хеликобактериоза у взрослых и детей). Руководство для врачей. Экспериментальная и клиническая гастроэнтерология. 2024;(12):49-145 [Lazebnik LB, Dekhnich NN, Sitkin SI, et al. Helicobacter pylori, helicobacteriosis and associated diseases (VIII Moscow Agreements on the diagnosis and treatment of helicobacteriosis in adults and children). A Clinical Guide for Physicians. Experimental and Clinical Gastroenterology. 2024;(12):49-145 (in Russian)]. DOI:10.31146/1682-8658-ecg-232-12-49-145
35. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32(9):1069-79. Erratum in: Aliment Pharmacol Ther. 2010;32(11-12):1408. DOI:10.1111/j.1365-2036.2010.04457.x
36. Wang F, Feng J, Chen P, et al. Probiotics in Helicobacter pylori eradication therapy: Systematic review and network meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(4):466-75. DOI:10.1016/j.clinre.2017.04.004
37. Lü M, Yu S, Deng J, et al. Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016;11(10):e0163743. DOI:10.1371/journal.pone.0163743
38. Zhang MM, Qian W, Qin YY, et al. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol. 2015;21(14):4345-57. DOI:10.3748/wjg.v21.i14.4345
39. Shi X, Zhang J, Mo L, et al. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore). 2019;98(15):e15180. DOI:10.1097/MD.0000000000015180
40. Viazis N, Argyriou K, Kotzampassi K, et al. A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates. Nutrients. 2022;14(3):632. DOI:10.3390/nu14030632
41. McNicholl AG, Molina-Infante J, Lucendo AJ, et al. Probiotic supplementation with Lactobacillus plantarum and Pedio-coccus acidilactici for Helicobacter pylori therapy: A randomized, double-blind, placebo-controlled trial. Helicobacter. 2018;23(5):e12529. DOI:10.1111/hel.12529
42. Poonyam P, Chotivitayatarakorn P, Vilaichone RK. High Effective of 14-Day High-Dose PPI-Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study. Asian Pac J Cancer Prev. 2019;20(9):2859-64. DOI:10.31557/APJCP.2019.20.9.2859
43. Yang C, Liang L, Lv P, et al. Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: A randomized double-blind placebo-controlled trial. Helicobacter. 2021;26(6):e12856. DOI:10.1111/hel.12856
44. Moreno Márquez C, Fernández Álvarez P, Valdés Delgado T, et al. Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lacto-bacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori. Rev Esp Enferm Dig. 2022;114(2):89-95. DOI:10.17235/reed.2021.7931/2021
45. Naghibzadeh N, Salmani F, Nomiri S, Tavakoli T. Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial. BMC Gastroenterol. 2022;22(1):107. DOI:10.1186/s12876-022-02187-z
46. Ismail NI, Nawawi KNM, Hsin DCC, et al. Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial. Helicobacter. 2023;28(6):e13017. DOI:10.1111/hel.13017
47. Mohtasham M, Joukar F, Maroufizadeh S, et al. Lactobacillus ruteri compared with placebo as an adjuvant in quadruple therapy for Helicobacter pylori eradication: A randomized, double-blind, controlled trial. Arab J Gastroenterol. 2023;24(1):40-4. DOI:10.1016/j.ajg.2022.10.004
48. Seddik H, Boutallaka H, Elkoti I, et al. Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial. Eur J Clin Pharmacol. 2019;75:639-45. DOI:10.1007/s00228-019-02625-0
49. He CX, Kong FT, Liang F, et al. Influence of different timing of Saccharomyces boulardii combined with bismuth quadruple therapy for Helicobacter pylori eradication. Zhonghua Yi Xue Za Zhi. 2019;99(22):1731-4 (in Chineze)]. DOI:10.3760/cma.j.issn.0376-2491.2019.22.010
50. Chang YW, Park YM, Oh CH, et al. Effects of probiotics or broccoli supplementation on Helicobacter pylori eradication with standard clarithromycin-based triple therapy. Korean J Intern Med. 2020;35:574-81. DOI:10.3904/kjim.2019.139
51. Суворов А.Н., Барышникова Н.В., Сварваль А.В., Ниязов Р.М. Возможности некоторых пробиотических штаммов в эрадикации Helicobacter pylori in vitro и in vivo. Фарматека. 2018;(2):74-8 [Suvorov AN, Baryshnikova NV, Svarval AV, Niyazov RM. Possibilities of some probiotic strains in the eradication of Helicobacter pylori in vitro and in vivo. Pharmateca. 2018;(2):74-8 (in Russian)]. DOI:10.18565/pharmateca.2018.2.74–78
52. Ermolenko EI, Molostova AS, Baryshnikova NV, et al. The clinical effectiveness of probiotics and autoprobiotics in treatment of Helicobacter pylori-associated dyspepsia. Russian Journal of Infection and Immunity. 2022;12(4):726-34. DOI:10.15789/2220-7619-TCE-1927
53. Losurdo G, Cubisino R, Barone M, et al. Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis. World J Gastroenterol. 2018;24:139-49. DOI:10.3748/wjg.v24.i1.139
54. Penumetcha SS, Ahluwalia S, Irfan R, et al. The Efficacy of Probiotics in the Management of Helicobacter Pylori: A Systematic Review. Cureus. 2021;13:e20483. DOI:10.7759/cureus.20483
55. Baryshnikova NV, Ilina AS, Ermolenko EI, et al. Probiotics and autoprobiotics for treatment of Helicobacter pylori infection. World J Clin Cases. 2023;11(20):4740-51. DOI:10.12998/wjcc.v11.i20.4740
56. Baryshnikova N, Ermolenko E, Svarval A, et al. Enterococcus faecium L-3 in Eradication of Helicobacter pylori: In-vivo and In-vitro. Int J Clin Med Microbiol. 2017;2:123. DOI:10.15344/2456-4028/2017/123
57. Suvorov A, Karaseva A, Kotyleva M, et al. Autoprobiotics as an approach for restoration of personalised microbiota. Front Microbiol. 2018;9:1869. DOI:10.3389/fmicb.2018.01869
58. Боровкова Е.А., Алиева Е.В. Микробиологическое исследование микрофлоры толстого кишечника на дисбактериоз в оценке эффективности аутопробиотикотерапии. Естественные и  технические науки. 2020;8(146):24-33 [Borovkova EA, Alieva EV. Mikrobiologicheskoe issledovanie mikroflory tolstogo kishechnika na disbakterioz v otsenke effektivnosti autoprobiotikoterapii. Estestvennye i tekhnicheskie nauki. 2020;8(146):24-33 (in Russian)]. 
59. Цапиева А.Н., Боровкова Е.А., Карасева А.Б., и др. Разработка метода идентификации индигенных лактобацилл кишечника при создании аутопробиотиков. Вопросы детской диетологии. 2019;17(3):52-9 [Tsapieva AN, Borovkova EA, Karaseva AB, et al. Razrabotka metoda identifikatsii indigennykh laktobatsill kishechnika pri sozdanii autoprobiotikov. Voprosy detskoi dietologii. 2019;17(3):52-9 (in Russian)]. DOI:10.20953/1727-5784-2019-3-52-59
60. Ermolenko EI, Abdurasulova IN, Kotyleva MP, et al. Effects of Indigenous Enterococci on the Intestinal Microbiota and the Behavior of Rats. Neuroscience and Behavioral Physiology. 2018;48(4):496-505. DOI:10.1007/s11055-018-0591
61. Всемирная гастроэнтерологическая организация. Практические рекомендации «Пробиотики и пребиотики». Режим доступа: https://www.worldgastroenterology.org/guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-russian. Ссылка активна на 19.03.2025 [Vsemirnaia gastroenterologicheskaia organizatsiia. Prakticheskie rekomendatsii "Probiotiki i prebiotiki". Available at: https://www.worldgastroenterology.org/guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics.... Accessed: 19.03.2025 (in Russian)].
62. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125(6):1401-12. DOI:10.1093/jn/125.6.1401

________________________________________________

1. Klinicheskie rekomendatsii MZ RF «Gastrit i duodenit», 2024. Available at: https://cr.minzdrav.gov.ru/preview-cr/708_2. Accessed: 19.03.2025 (in Russian). 
2. Ivashkin VT, Maev IV, Lapina TL, et al. Clinical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70-99 (in Russian). DOI:10.22416/1382-4376-2021-31-4-70-99
3. Osipenko MF, Bikbulatova EA, Shakalite YuD, et al. Resistance of Helicobacter pylori to  clarithromycin in Novosibirsk. Experimental and Clinical Gastroenterology. 2012;8:15-7 (in Russian). EDN: SEPVAB
4. Simanenkov VI, Zakharova NV, Zhebrun AB, et al. Resistance of Helicobacter pylori to antimicrobial drugs according to the results of bacteriological testing. Lechashchii vrach. 2015;4:91-5 (in Russian). EDN: TPLKMR
5. Baryshnikova NV, Denisova EV, Kornienko EA, et al. Epidemiological study of Helicobacter pylori resistance to clarithromycin in St. Petersburg residents with peptic ulcer disease. Experimental and Clinical Gastroenterology. 2009;5:73-6 (in Russian). EDN: MVAHWR
6. Sun Q, Liang X, Zheng Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010;15(3):233-8. DOI:10.1111/j.1523-5378.2010.00758.x
7. Malfertheiner P. Infection: Bismuth improves PPI-based triple therapy for H. pylori eradication. Nat Rev Gastroenterol Hepatol. 2010;7(10):538-9. DOI:10.1038/nrgastro.2010.131
8. McNicholl AG, Bordin DS, Lucendo A, et al. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clin Gastroenterol Hepatol. 2020;18(1):89-98. DOI:10.1016/j.cgh.2019.03.048
9. Tkachenko EI, Uspenskii YuP, Baryshnikova NV. Optimization of treatment of patients with diseases associated with Helicobacter pylori infection: justification of the need to use bismuth preparations. Experimental and Clinical Gastroenterology. 2009;6:116-21 (in Russian). EDN: YQIDJV
10. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 1988;2(8626-7):1437-42. DOI:10.1016/s0140-6736(88)90929-4
11. Lazebnik LB, Vasilev YuV, Shcherbakov PL, et al. Helicobacter pylori: prevalence, diagnosis, treatment. Experimental and Clinical Gastroenterology. 2010;(2):3-7 (in Russian). EDN: MVAIIF
12. Khomeriki NM, Morozov IA. Peculiarities of cytoprotection in the stomach and some aspects of pharmacological action of bismuth drugs. Medical Council. 2017;(11):112-9 (in Russian). DOI:10.21518/2079-701X-2017-112-119 
13. Bagchi D, McGinn TR, Ye X, et al. Mechanism of gastroprotection by bismuth subsalicylate against chemically induced oxidative stress in cultured human gastric mucosal cells. Dig Dis Sci. 1999;44(12):2419-28. DOI:10.1023/a:1026618501729
14. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261-70. DOI:10.1586/egh.10.25
15. Haruma K, Ito M. Review article: clinical significance of mucosal-protective agents: acid, inflammation, carcinogenesis and rebamipide. Aliment Pharmacol Ther. 2003;18(Suppl. 1):153-9. DOI:10.1046/j.1365-2036.18.s1.17.x
16. Hayashi S, Sugiyama T, Amano K, et al. Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother. 1998;42(8):1895-9. DOI:10.1128/AAC.42.8.1895
17. Andreev DN, Maev IV, Dicheva DT. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med. 2019;8(9):1498. DOI:10.3390/jcm8091498
18. Hayashi S, Sugiyama T, Yokota K, et al. Combined effect of rebamipide and ecabet sodium on Helicobacter pylori adhesion to gastric epithelial cells. Microbiol Immunol. 2000;44(7):557-62. DOI:10.1111/j.1348-0421.2000.tb02534.x
19. Arakawa T, Higuchi K, Fujiwara Y, et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50(Suppl. 1):S3-S11. DOI:10.1007/s10620-005-2800-9
20. Haruma K, Ito M, Kido S, et al. Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci. 2002;47(4):862-7. DOI:10.1023/a:1014716822702
21. Kamada T, Sato M, Tokutomi T, et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015;2015:865146. DOI:10.1155/2015/865146
22. Simanenkov VI, Maev IV, Tkacheva ON, et al. Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(8):940-56 (in Russian). DOI:10.26442/00403660.2022.08.201523
23. Ohashi H, Maruyama T, Higashi-Matsumoto H, et al. A novel binding assay for metabotropic glutamate receptors using [3H] L-quisqualic acid and recombinant receptors. Z Naturforsch C J Biosci. 2002;57(3-4):348-55. DOI:10.1515/znc-2002-3-425
24. Shevtsov MA, Smagina LV, Kudriavtceva TA, et al. Glu-Trp-ONa or its acylated analogue (R-Glu-Trp-ONa) administration enhances the wound healing in the model of chronic skin wounds in rabbits. Drug Des Devel Ther. 2015;9:1717-27. DOI:10.2147/DDDT.S79665
25. Uspensky YP, Baryshnikova NV, Krasnov AA, et al. Topical issues of prevention of stomach cancer. Consilium medicum. 2022;24(5):357-64 (in Russian). DOI:10.26442/20751753.2022.5.201922
26. Uspensky Yu P, Baryshnikova NV, Krasnov AA, et al. The effect of Regasthym Gastro on the restoration of acid production in the stomach according to daily pH-metry in patients with chronic atrophic gastritis. Experimental and Clinical Gastroenterology. 2022;198(2):40-7 (in Russian). DOI:10.31146/1682-8658-ecg-198-2-40-47
27. Uspensky YP, Baryshnikova NV, Fominykh YA, et al. Alpha-Glutamyl-Tryptophan in the treatment of chronic atrophic gastritis, associated with Helicobacter pylori. From the edited volume «Helicobacter pylori Infection – An Up to Date on the Pathogenic Mechanisms, Diagnosis and Clinical Management». Available at: https://www.intechopen.com/online-first/84437. Accessed: 06.03.2024.
28. Baryshnikova NV, Uspensky YuP, Kalinina EYu, et al. The effectiveness of alpha-glutamyl-tryptophan in relieving inflammation in patients with chronic atrophic gastritis associated with Helicobacter pylori. Dokasatelnaya Gastroenterologia. 2022;11(4):15-21 (in Russian). DOI:10.17116/dokgastro20221104115. 
29. Tkachenko EI, Uspenskiy YuP, Baryshnikova NV. Optimization of treatment for Helicobacter pylori-associated diseases. Vrach. 2012; 1:36-8 (in Russian).
30. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut. 2012;61(5):646-64. DOI:10.1136/gutjnl-2012-302084
31. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. DOI:10.1136/gutjnl-2016-312288
32. Malfertheiner P, Megraud F, Rokkas T; European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;gutjnl-2022-327745. DOI:10.1136/gutjnl-2022-327745
33. Ivashkin VT, Lapina TL, Maev IV, et al. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for Н. pylori Diagnostics and Treatment in Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):72-93 (in Russian). DOI:10.22416/1382-4376-2022-32-6-72-93
34. Lazebnik LB, Dekhnich NN, Sitkin SI, et al. Helicobacter pylori, helicobacteriosis and associated diseases (VIII Moscow Agreements on the diagnosis and treatment of helicobacteriosis in adults and children). A Clinical Guide for Physicians. Experimental and Clinical Gastroenterology. 2024;(12):49-145 (in Russian). DOI:10.31146/1682-8658-ecg-232-12-49-145
35. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32(9):1069-79. Erratum in: Aliment Pharmacol Ther. 2010;32(11-12):1408. DOI:10.1111/j.1365-2036.2010.04457.x
36. Wang F, Feng J, Chen P, et al. Probiotics in Helicobacter pylori eradication therapy: Systematic review and network meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(4):466-75. DOI:10.1016/j.clinre.2017.04.004
37. Lü M, Yu S, Deng J, et al. Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016;11(10):e0163743. DOI:10.1371/journal.pone.0163743
38. Zhang MM, Qian W, Qin YY, et al. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol. 2015;21(14):4345-57. DOI:10.3748/wjg.v21.i14.4345
39. Shi X, Zhang J, Mo L, et al. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore). 2019;98(15):e15180. DOI:10.1097/MD.0000000000015180
40. Viazis N, Argyriou K, Kotzampassi K, et al. A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates. Nutrients. 2022;14(3):632. DOI:10.3390/nu14030632
41. McNicholl AG, Molina-Infante J, Lucendo AJ, et al. Probiotic supplementation with Lactobacillus plantarum and Pedio-coccus acidilactici for Helicobacter pylori therapy: A randomized, double-blind, placebo-controlled trial. Helicobacter. 2018;23(5):e12529. DOI:10.1111/hel.12529
42. Poonyam P, Chotivitayatarakorn P, Vilaichone RK. High Effective of 14-Day High-Dose PPI-Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study. Asian Pac J Cancer Prev. 2019;20(9):2859-64. DOI:10.31557/APJCP.2019.20.9.2859
43. Yang C, Liang L, Lv P, et al. Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: A randomized double-blind placebo-controlled trial. Helicobacter. 2021;26(6):e12856. DOI:10.1111/hel.12856
44. Moreno Márquez C, Fernández Álvarez P, Valdés Delgado T, et al. Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lacto-bacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori. Rev Esp Enferm Dig. 2022;114(2):89-95. DOI:10.17235/reed.2021.7931/2021
45. Naghibzadeh N, Salmani F, Nomiri S, Tavakoli T. Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial. BMC Gastroenterol. 2022;22(1):107. DOI:10.1186/s12876-022-02187-z
46. Ismail NI, Nawawi KNM, Hsin DCC, et al. Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial. Helicobacter. 2023;28(6):e13017. DOI:10.1111/hel.13017
47. Mohtasham M, Joukar F, Maroufizadeh S, et al. Lactobacillus ruteri compared with placebo as an adjuvant in quadruple therapy for Helicobacter pylori eradication: A randomized, double-blind, controlled trial. Arab J Gastroenterol. 2023;24(1):40-4. DOI:10.1016/j.ajg.2022.10.004
48. Seddik H, Boutallaka H, Elkoti I, et al. Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial. Eur J Clin Pharmacol. 2019;75:639-45. DOI:10.1007/s00228-019-02625-0
49. He CX, Kong FT, Liang F, et al. Influence of different timing of Saccharomyces boulardii combined with bismuth quadruple therapy for Helicobacter pylori eradication. Zhonghua Yi Xue Za Zhi. 2019;99(22):1731-4 (in Chineze)]. DOI:10.3760/cma.j.issn.0376-2491.2019.22.010
50. Chang YW, Park YM, Oh CH, et al. Effects of probiotics or broccoli supplementation on Helicobacter pylori eradication with standard clarithromycin-based triple therapy. Korean J Intern Med. 2020;35:574-81. DOI:10.3904/kjim.2019.139
51. Suvorov AN, Baryshnikova NV, Svarval AV, Niyazov RM. Possibilities of some probiotic strains in the eradication of Helicobacter pylori in vitro and in vivo. Pharmateca. 2018;(2):74-8 (in Russian). DOI:10.18565/pharmateca.2018.2.74–78
52. Ermolenko EI, Molostova AS, Baryshnikova NV, et al. The clinical effectiveness of probiotics and autoprobiotics in treatment of Helicobacter pylori-associated dyspepsia. Russian Journal of Infection and Immunity. 2022;12(4):726-34. DOI:10.15789/2220-7619-TCE-1927
53. Losurdo G, Cubisino R, Barone M, et al. Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis. World J Gastroenterol. 2018;24:139-49. DOI:10.3748/wjg.v24.i1.139
54. Penumetcha SS, Ahluwalia S, Irfan R, et al. The Efficacy of Probiotics in the Management of Helicobacter Pylori: A Systematic Review. Cureus. 2021;13:e20483. DOI:10.7759/cureus.20483
55. Baryshnikova NV, Ilina AS, Ermolenko EI, et al. Probiotics and autoprobiotics for treatment of Helicobacter pylori infection. World J Clin Cases. 2023;11(20):4740-51. DOI:10.12998/wjcc.v11.i20.4740
56. Baryshnikova N, Ermolenko E, Svarval A, et al. Enterococcus faecium L-3 in Eradication of Helicobacter pylori: In-vivo and In-vitro. Int J Clin Med Microbiol. 2017;2:123. DOI:10.15344/2456-4028/2017/123
57. Suvorov A, Karaseva A, Kotyleva M, et al. Autoprobiotics as an approach for restoration of personalised microbiota. Front Microbiol. 2018;9:1869. DOI:10.3389/fmicb.2018.01869
58. Borovkova EA, Alieva EV. Mikrobiologicheskoe issledovanie mikroflory tolstogo kishechnika na disbakterioz v otsenke effektivnosti autoprobiotikoterapii. Estestvennye i tekhnicheskie nauki. 2020;8(146):24-33 (in Russian). 
59. Tsapieva AN, Borovkova EA, Karaseva AB, et al. Razrabotka metoda identifikatsii indigennykh laktobatsill kishechnika pri sozdanii autoprobiotikov. Voprosy detskoi dietologii. 2019;17(3):52-9 (in Russian). DOI:10.20953/1727-5784-2019-3-52-59
60. Ermolenko EI, Abdurasulova IN, Kotyleva MP, et al. Effects of Indigenous Enterococci on the Intestinal Microbiota and the Behavior of Rats. Neuroscience and Behavioral Physiology. 2018;48(4):496-505. DOI:10.1007/s11055-018-0591
61. Vsemirnaia gastroenterologicheskaia organizatsiia. Prakticheskie rekomendatsii "Probiotiki i prebiotiki". Available at: https://www.worldgastroenterology.org/guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics.... Accessed: 19.03.2025 (in Russian).
62. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125(6):1401-12. DOI:10.1093/jn/125.6.1401

Н.В. Барышникова*^1–3, А.С. Ильина^3,4, Ю.П. Успенский^1,2, А.Н. Суворов³, Е.И. Ермоленко<sup>3,5

1</sup>ФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава России, Санкт-Петербург, Россия;
²ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, Санкт-Петербург, Россия;
³ФГБНУ «Институт экспериментальной медицины» Минобрнауки России, Санкт-Петербург, Россия;
⁴ФГБУ «Северо-Западный окружной научно-клинический центр им. Л.Г. Соколова» ФМБА России, Санкт-Петербург, Россия;
⁵ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России, Санкт-Петербург, Россия
*baryshnikova_nv@mail.ru

________________________________________________

Natalia V. Baryshnikova*^1–3, Anastasiia S. Ilina^3,4, Yury P. Uspenskiy^1,2, Alexander N. Suvorov³, Elena I. Ermolenko<sup>3,5

1</sup>Saint Petersburg State Pediatric Medical University, Saint Petersburg, Russia;
²Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia;
³Institute of Experimental Medicine, Saint Petersburg, Russia;
⁴Sokolov North-Western District Scientific and Clinical Center, Saint Petersburg, Russia;
⁵Mechnikov North-Western State Medical University, Saint Petersburg, Russia
*baryshnikova_nv@mail.ru